biotech / news / / MarketScreener
AstraZeneca beat first-quarter sales and profit expectations.
AstraZeneca's Q1 core earnings were $2.58 per share, beating analyst expectations of $2.54.
KEY POINTS
- Total Q1 revenue reached $15.29 billion, surpassing the consensus estimate of $14.9 billion.
- AstraZeneca is maintaining its 2026 financial outlook despite geopolitical and industry challenges.
- Cancer drug demand and investments in the U.S. and China are driving AstraZeneca's growth.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →